A third of companies lack compliance departments

A new pharmaceutical compliance report shows that less than two-thirds of pharma companies have dedicated compliance departments. "There is no doubt in my mind that companies with dedicated compliance departments are better prepared to handle and adapt to these changes," said lead author David Richardson, senior analyst for Cutting Edge Information. Release

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.